top of page


South Korea approves Jascayd nerandomilast for idiopathic pulmonary fibrosis
South Korea has authorised Jascayd (nerandomilast) for idiopathic pulmonary fibrosis, providing a new national treatment option for patients with progressive lung scarring.

nuaxia
Oct 162 min read


South Korean doctors earn ₩285.18 million a year, latest government data show
South Korea has published its latest official healthcare workforce survey, providing a new government benchmark for physician remuneration and working conditions across the country's healthcare system.

nuaxia
Oct 24 min read
bottom of page